Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These gastrointestinal adverse events are poorly documented in the literature due to their low frequency [6].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose‐dependent relationship [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [66]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global clinical measure of fitness and frailty in elderly people
Rockwood, K. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050051 · Cited by 8,968 · cited 1×
“The Clinical Frailty Scale may sometimes be useful to guide dose adjustment [75].”
MethodLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“CKD increases the risk of GLP-1 RA-associated diarrhoea, with symptoms being more severe with albuminuria [84].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
BackgroundResultSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney di…”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
Background
Research works printed but not linked: 2
- 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
- 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119
Cited by
Items 101–200 of 355
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
“However, these could be managed through patient education, proper dose escalation protocols, and symptomatic treatment [49].”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“An expert consensus statement suggests that, although pancreatic and gallbladder adverse events are extremely infrequent, caution is warranted in patients with a history of such disorders 44 .”
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“79,80 Dose escalation schedules should follow manufacturer recommendations, which vary by formulation (Table 3).”
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70–85% of patients and lead to treatment discontinuation [22,38,41,60,61].”
InfluentialVilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Motil, K. J., Beisang, A., Smith‐Hicks, C. L., Lembo, A. J., Standridge, S. M., & Liu, E. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2368014 · Cited by 9
“However, it is of interest to speculate that trofinetide may have a neuroendocrine effect in the gut, similar to GLP-1 RA drugs, which also may be associated with nausea and vomiting due to delayed gastric emptying (gastro-paresis) [47].”
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
“Following specific dietary recommendations such as eating slowly, smaller and low-fat meals, and increased fiber intake can alleviate symptoms [51].”
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?
Chavez, A. M., Barria, R. C., & León-Sanz, M. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001130 · Cited by 30
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes
Sarwal, A., Singh, R., Wei, G., Shen, J., Nevers, M. R., Hartsell, S. E., Derington, C. G., Takyi, A., Chakravartula, A. R., Katkam, N., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16642 · Cited by 8
Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives
Liu, Y., Zhang, M., & Wang, Y. (2025) · Biology · doi:10.3390/biology14080989 · Cited by 15
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“Such side effects are a class effect of GLP-1 receptor mono-agonists, 154,155 and it is currently unclear if they occur at a higher rate with GCGR-based dual and triple agonists.”
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
“50 51 – 53 The same strategies will likely be followed for glucagon receptor/GLP-1 receptor dual agonists, informed by the ongoing phase 3 trials and further insights from real-world experience.”
Lee, N., & Kim, Y. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70163 · Cited by 14
“First, rapid weight loss observed in some patients using sem-aglutide has been suggested as a potential contributing factor for telogen effluvium, a transient diffuse shedding of hair following physiological stress such as caloric restriction or bariatric surgery [17–19].”
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
“The GI adverse effects range from nausea, vomiting, diarrhea and constipation, with nausea being the most common among several clinical trials [50].”
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15725 · Cited by 11
“31 An intriguing concept emerging from this analysis entails the implementation of a synergistic strategy involving once-weekly insulin to minimize the need for higher tirzepatide doses and improve adherence and tolerability of the medication.”
Fan, Y., Yuan, J., Dong, L., Yu, C., Ding, H., Xie, D., Guan, R., Li, R., Zou, W., Long, S., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16203 · Cited by 8
“9 The combined activation of GLP-1R and GIPR can synergistically and complementarily act on pancreatic β cells through different metabolic roles, reducing the dependence on GLP-1 mediated effects and gastrointestinal side effects.”
Lopez, R. F. R., Barrera, D. L., Muñoz, M. C. A., & Díaz, M. (2025) · Cureus · doi:10.7759/cureus.90021 · Cited by 17
“Some authors have begun exploring emerging dermatological manifestations related to these drugs from different perspectives. but also highlighted that proper management of adverse outcomes can significantly improve treatment adherence and persistence, ultimately enhancing quality of life [5].”
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedFloegel‐Shetty, A. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.478 · Cited by 6
Sex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
“1D) 41,42 .”
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Witaszek, T., Biesiada, A. M., Iskra-Trifunović, J., Babicki, M., Mastalerz–Migas, A., & Kłoda, K. (2025) · Biomedicines · doi:10.3390/biomedicines13102362 · Cited by 8
“Key vulnerable groups include frail individuals and those with pre-existing GI disorders or gallbladder disease [28].”
InfluentialMcMath, A. L., & Gallagher, D. (2025) · Obesity Reviews · doi:10.1111/obr.70041 · Cited by 8
“The most common adverse event reported with the use of GLP-1 RAs is mild to moderate gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation [86].”
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 11
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
“Finally, persistent, severe, or progressive symptoms should prompt medical reassessment, consideration of dose-escalation delay or dose adjustment, and evaluation for alternative diagnoses or complications rather than relying on dietary modification alone [40,56,121].”
InfluentialSaeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Jones, M., & Cappola, J. J. (2025) · Cureus · doi:10.7759/cureus.81891 · Cited by 16
de Lucas, M. D. G., Caballero, I., Fernández‐García, J. C., Domínguez-Rodríguez, M., Moreno-Moreno, P., Jiménez-Millán, A., Botana-López, M. A., Avilés, B., Merino-Torres, J. F., Soto, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240279 · Cited by 10
Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5
“When managing obesity and weight-related conditions, comprehensive care could be achieved by incorporating registered dietitians, clinicians, lifestyle counselors, and integrating communication with patients to optimize outcomes and proactively manage IBT AEs [114,115].”
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5
“[2] According to certain studies, the negative GI side effects of GLP-1 RAs are dose-dependent and gradually lessen.”
Lee, S., Kim, H., Choi, I., Lee, S., & Min, K. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118102 · Cited by 5
Kennedy, C., Moyer, K., & Herdes, R. E. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11356 · Cited by 8
“…nutrients and are better tolerated (bake, grill, boil, air fry) 19 • Eat smaller, more frequent meals and snacks (4 – 6 per day) 62,63 • Incorporate mindful eating practices (chewing well, eating slowly, recognizing feelings of satiety) 18,19 • Prioritize whole foods rather than processed products.”
InfluentialIncrease in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients
Khan, U., Brønstad, I., Hillestad, E. M. R., Steinsvik, E. K., Hausken, T., Berentsen, B., & Lied, G. A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1615671 · Cited by 6
Ponzo, V., Vitale, M., Bo, S., Broglio, F., Goitre, I., & Cioffi, I. (2025) · Nutrients · doi:10.3390/nu17213318 · Cited by 7
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“This phenomenon could worsen pre-existing eating disorders, as rapid weight loss may lead to concerns about body image, potentially giving rise to issues related to self-perception [68].”
Climate Change, Air Pollution and the Global Obesity Syndemic: a Review of Current Evidence
Vallianou, N. G., Kounatidis, D. C., Geladari, E. V., Evangelopoulos, A. A., Kaldis, V., Stratigou, T., Evangelopoulos, A. A., Karampela, Ι., & Dalamaga, Μ. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00671-7 · Cited by 7
“As gastrointestinal side effects occur more commonly during the early phases of GLP-1 receptor agonists treatment, and with titrating the doses, clinicians should make patients particularly aware in order to avoid gross dehydration potentially requiring hospitalization [139–141].”
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 7
“22 If counselling on dietary behaviours and medications to control adverse gastrointestinal symptoms do not sufficiently mitigate such symptoms, actions can include temporary inter-ruption of treatment, followed by temporary dose reduction or delay of a scheduled up-titration and a subsequent…”
Islam, M. S., Monir, S. B., Haque, N., Vabna, M. A., Fan, J., Li, Y., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710157 · Cited by 12
Potential role of glucagon like peptide 1 in taste receptors
Doval-Caballero, J. L. E., Ferreira‐Hermosillo, A., Eugenio-Ponce, G. D., García-Sáenz, M. R., Ibarra‐Salce, R., Tenorio-Rojo, A. P., Luna-Ávila, E. S., Palacios, P. C. G., Pérez-Hernández, F., Rojas-Milán, E., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1683419 · Cited by 10
Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
Laren, J. V., Friesleben, C. R., Gershovich, O. E., Helm, L. A., Patel, R. J., & Delate, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70579 · Cited by 7
“24,25 Evidence to support these concepts is limited with findings dependent on the studied population.”
InfluentialEpigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management
Chaudhry, M., & Sif, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01831-1 · Cited by 7
“Although these symptoms are often short lived, they can negatively impact patient adherence and overall treatment satisfaction [133].”
Mind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment
Hubert, P. A., Coleman, C. D., Grosicki, G. J., Kiel, J., Shepherd, M., Lofton, H. F., Heymsfield, S. B., Thomas, J. G., Dhurandhar, N. V., & Jonnalagadda, S. S. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156366 · Cited by 5
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Sforzo, G. A., Gordon, N. F., Peeke, P. M., & Moore, M. A. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241302273 · Cited by 8
GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic InterventionsPreprint
Cao, K. (2025) · Preprints.org · doi:10.20944/preprints202506.1838.v1 · Cited by 5
Playford, R. J. (2024) · Nutrients · doi:10.3390/nu16213684 · Cited by 4
Marshall, L. Z., Gleason, P. P., Friedlander, N., Farley, J., & Urick, B. Y. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.281 · Cited by 6
Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists
Shah, M. Y., Mohammad, A., Samejo, R. B. A., Rana, S., Singla, S., Aurangzeb, R. I., Tariq, M. M., Zamir, M. H., Farooq, U., Aurangzeb, R. F., et al. (2025) · Cureus · doi:10.7759/cureus.88334 · Cited by 12
“Although GLP-1 RAs are generally well tolerated, gastrointestinal adverse effects - including nausea, vomiting, and diarrhea - remain the most common side effects, leading to higher discontinuation rates, particularly in early treatment phases [19].”
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
“20 As a result, nearly 70% of patients discontinue treatment by the end of the first year, based on prescriber data studies.”
Setyawan, H. Y., Singh, A. K., Roy, A., Pandit, S., Gill, H. S., Rajeev, M., Rustagi, S., & Hee, C. W. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100926 · Cited by 5
Noordam, C., Eiholzer, U., Katschnig, C. K., Stasinaki, A., & Dubinski, I. (2025) · Children · doi:10.3390/children12121716 · Cited by 5
“Furthermore, general measures to reduce nausea should always be integrated into treatment information and initiation (e.g., advice on eating habits, food composition and lifestyle) [34].”
Alharbi, S., & Alkhalifah, A. (2026) · Skin Appendage Disorders · doi:10.1159/000550540 · Cited by 6
“Gastrointestinal side effects such as nausea, vomiting, and diarrhea are the most common and well-documented adverse events [11].”
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
“GI adverse effects are common with GLP-1RA, with clinical trials reporting incidences of 40% to 70% and some protocols reporting ≤ 85% [11].”
InfluentialHRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 5
Achieving equitable access to incretin-based therapies in cardiovascular care
Reddy, T. K., Villavaso, C. D., Pulapaka, A. V., & Ferdinand, K. C. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100455 · Cited by 11
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Abdelrahman, A. M., Awad, A. S., Hasan, I., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247732 · Cited by 4
“In a recent Spanish study [68] focusing on the gastrointestinal adverse events in patients receiving GLP-1 RAs, a panel of researchers convened virtually to adopt practical guidelines to follow during the initiation and dose escalation of GLP-1RAs and to recommend measures to deal with the GI…”
New Approaches to the Treatment of Severe Obesity—Prehabilitation as the Key to Success
Budny, A., Janczy, A., & Mika, A. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00652-1 · Cited by 4
Ouyang, Z., Han, Z. Y., Xu, D., Yan, B., Wang, J., Ye, S., Wu, S., & Qiao, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145476 · Cited by 6
Liu, B., Huang, R., Zhang, W., Tian, J. H., Xian, Y., & Chen, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-02394-0 · Cited by 7
Frazer, M., Swift, C., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., Noone, J. M., & Gamble, C. L. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01341-y · Cited by 4
“Providers can help patients manage adverse events (AEs), with mild GI AEs (e.g., nausea) managed with recommended lifestyle changes, dose-dependent AEs managed by modifying the dosing schedule, and more severe AEs (e.g., severe diarrhea, persistent vomiting) evaluated and treated medically [30].”
BackgroundJoshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
“According to recent research, compared to bupropion-naltrexone, using GLP-1RAs for weight reduction carries a greater risk of pancreatitis, gastroparesis, and intestinal obstruction [21,22] .”
ResultOdoardo, L. A. F. D., Zucchetti, O., Sciatti, E., D’Isa, S., D’Elia, E., & Senni, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf032 · Cited by 6
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
Kimura, T., Kubo, M., Takahashi, K., Wamata, R., Iwamoto, Y., Iwamoto, H., Katakura, Y., Sanada, J., Fushimi, Y., Shimoda, M., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5880589 · Cited by 4
“It is known, however, that semaglutide has more side e ff ects such as gastrointestinal symptoms compared to dulaglutide especially in elderly subjects [31, 32].”
BackgroundAyesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100284 · Cited by 5
“Literature reports indicate that GLP-RAs are linked with adverse effects, notably during dose escalation [21].”
BackgroundInceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
“Other concerns include an increased risk of thyroid C-cell tumors, although this has been seen mainly in animal studies, and human data have not confirmed this risk [18].”
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
Introducing a Novel Once-weekly Dipeptidyl Peptidase 4 Inhibitor: Trelagliptin in India
Dewan, B., Navale, S., Shinde, S., & Ganiga, R. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1093 · Cited by 3
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Basavarajappa, S. D., Girijashankar, H. B., Joshi, A., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112830 · Cited by 4
Current clinical application of incretin therapy for obesity management
Skinner, K., & Clements, J. N. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0152 · Cited by 5
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
Miller, J., Miller, R., Varney, S. M., & Han, D. C. (2026) · Journal of Medical Toxicology · doi:10.1007/s13181-026-01121-z · Cited by 4
“These conditions often required switching between formulations, using compounded products with non-standard or unknown concentrations [ 27, 28], or rationing doses, any of which could increase the likelihood of error independent of patient intent [ 29].”
Monzo, L., Savarese, G., Müllens, W., Abdelhamid, M., Antohi, E., Jhund, P. S., Iacoviello, M., Jankowska, E. A., Lee, M. M. Y., Lindberg, F., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag027 · Cited by 5
Glucagon-like peptide-1 receptor agonists: a review of the literature from a dental perspective
O'Driscoll, J. A., & McIntyre, G. T. (2026) · BDJ · doi:10.1038/s41415-025-9345-4 · Cited by 4
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications
Kofman, K., & Ouanounou, A. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.03.008 · Cited by 6
Olsen, M. B., GRIFFIN, J., Hövelmann, U., Macura, S., Hagen, B. F., Hesse, D., & Heise, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70753 · Cited by 4
“Despite the use of dose escalation to mitigate this type of AE [7], real-world data indicate GLP-1 RA discontinuation rates to be approximately 50%–75% within 12 months [8].”
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“In patients with nausea or early fullness, temporary use of smaller meals, slower eating pace, reduced meal fat load, and avoidance of large mixed meals may improve tolerability [86,87].”
InfluentialNewer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Bartoszko, J. M., & van Klei, W. A. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02809-y · Cited by 3
Joshi, G. P. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005222 · Cited by 4
A novel free fatty acid receptor agonist improving metabolic health in Drosophila models
Brunetti, K., Catalani, E., Quondam, S. D., Romano, N., Ceci, M., Clerici, G., Gordin, M., Bianchini, G., Brandolini, L., Aramini, A., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107769 · Cited by 3
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
“Discontinuation of GLP-1 medications is as high as 12% though permanent discontinuation is somewhere between 1.6–6% in clinical trials [75].”
InfluentialA Case Report of Acute Pancreatitis in Food-Induced Anaphylaxis
Wiese, J., Dakkak, B., Ugonabo, O. S., El-Dallal, M., & Frandah, W. (2024) · Cureus · doi:10.7759/cureus.71017 · Cited by 3
“According to the study by Gorgojo-Martinez and colleagues, nausea, vomiting, diarrhea, and constipation are the most frequently associated adverse effects of GLP-1 RA among gastrointestinal side effects [21].”
Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide
Iskander, M., Wadhwa, M., Kim, Y. J., Singh, N. C., & Pathak, P. (2025) · Cureus · doi:10.7759/cureus.78090 · Cited by 4
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“…to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
Ma, S., Fan, X., He, Y., Li, C., Qu, D., & Man, Y. (2023) · Trials · doi:10.1186/s13063-023-07678-2 · Cited by 4
“Currently, clinical caregivers heavily rely on empirical information and predominantly employ single intervention, including conservative strategies such as dietary modifications, bowel irrigation medication, or biofeed-back training [11–15].”
BackgroundGLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
Salazar, C. I. V., Lopez, S. Z. K., Rios, C. R., & Coutiño, L. F. G. (2025) · International Surgery Journal · doi:10.18203/2349-2902.isj20251200 · Cited by 2
Adverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, R., & Hasler, W. L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2579117 · Cited by 4
“The entries in this table represent the combined recommendations from several references cited in this article including [81], [87], [88], [89], and [111]. retained gastric contents (OR 6.30, 95% CI 5.30–7.49), and greater needs to abort (OR 5.50, 95% CI 3.25–9.32) or repeat (OR 2.19, 95% CI…”
InfluentialMai, Z., Kornak, J., Dufault, S. M., Strand, M. W., Reikes, A., & Watanabe, J. H. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251384637 · Cited by 2
“23,24,26 In addition, digestive system adverse events were found to generally have a negative association with adherence.”
Nahar, S., Maybee, N. A., Tamanna, N., Sadat, A., Khanam, F., Begum, R., Akther, S., Khan, M. S., Sonia, S. N., & Hasan, N. (2025) · Cureus · doi:10.7759/cureus.98935 · Cited by 3
“Nausea, vomiting, and constipation are well-documented adverse events of GLP-1 RAs, with reported incidences ranging from 15%-50%, 5%-20%, and 4%-12%, respectively [9].”
KHAN, A. R., Makhoul, G. W., & Raji, M. A. (2025) · Endocrine Regulations · doi:10.2478/enr-2025-0030 · Cited by 2
“A review found that gastrointestinal adverse events occur in 40% to 70% of patients leading to discontinuation in up to 12% of cases (Gorgojo-Martinez et al. 2022).”
Mercado, D. O., Fadda, M., Beltrame, B., Tosi, M., Bruno, A., Scala, C. D., Travaglia, G., Vitale, A., di Cola, R. S., Boschetti, S., et al. (2026) · Dietetics · doi:10.3390/dietetics5010017 · Cited by 2
“…general obesity guidelines (e.g., NICE, ADA, AACE) delineate integrated care pathways and indications for pharmacotherapy but provide fewer operational details for dietetic implementation (e.g., how to adjust energy/protein targets during drug-induced hypophagia or GI intolerance) [19,26,27,54,56].”
InfluentialTroshina, E. A., Antsiferov, M. B., As, A., Bakulin, I. G., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13784 · Cited by 2
Metadata
- Authors
- Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
- Affiliations
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
- Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
- Hospital Universitario La Paz (ES)
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
- Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Madrid Health Service (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Universitat de València (ES)
- Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-12-24
- Volume
- 12
- Issue
- 1
- Pages
- 145
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821052
- OpenAlex
- W4313260808
- Cited by
- 358
- References
- 83
- Citations by year
- 2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
- FWCI
- 40.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo-Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.